Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AMPH Stock Summary
Top 10 Correlated ETFs
AMPH
In the News
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
New Strong Sell Stocks for March 18th
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.73 per share a year ago.
Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
AMPH Financial details
AMPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.46 | 7.44 | 9.16 | 9.52 | 12.16 | |
Net income per share | 0.98 | 0.02 | 1.3 | 1.74 | 2.6 | |
Operating cash flow per share | 0.84 | 1.22 | 2.05 | 1.7 | 3.46 | |
Free cash flow per share | 0 | 0.5 | 1.48 | 1.24 | 2.74 | |
Cash per share | 1.71 | 2.25 | 2.86 | 3.35 | 4.89 | |
Book value per share | 7.64 | 8.55 | 9.33 | 10.08 | 12.06 | |
Tangible book value per share | 7.74 | 8.68 | 8.51 | 9.37 | 0.49 | |
Share holders equity per share | 7.64 | 8.55 | 9.33 | 10.08 | 12.06 | |
Interest debt per share | 1.34 | 1.44 | 2.21 | 1.99 | 11.75 | |
Market cap | 962.71M | 945.93M | 1.11B | 1.47B | 3.28B | |
Enterprise value | 955.65M | 920.56M | 1.09B | 1.42B | 3.76B | |
P/E ratio | 19.67 | 862.29 | 17.91 | 16.07 | 23.83 | |
Price to sales ratio | 2.99 | 2.7 | 2.54 | 2.94 | 5.09 | |
POCF ratio | 23.05 | 16.52 | 11.36 | 16.47 | 17.86 | |
PFCF ratio | 4.65K | 40.41 | 15.77 | 22.55 | 22.56 | |
P/B Ratio | 2.52 | 2.35 | 2.5 | 2.78 | 5.13 | |
PTB ratio | 2.52 | 2.35 | 2.5 | 2.78 | 5.13 | |
EV to sales | 2.96 | 2.63 | 2.49 | 2.84 | 5.83 | |
Enterprise value over EBITDA | -24.5K | 84.04 | 15.61 | 13.17 | 15.56 | |
EV to operating cash flow | 22.88 | 16.08 | 11.13 | 15.87 | 20.47 | |
EV to free cash flow | 4.62K | 39.32 | 15.47 | 21.73 | 25.85 | |
Earnings yield | 0.05 | 0 | 0.06 | 0.06 | 0.04 | |
Free cash flow yield | 0 | 0.02 | 0.06 | 0.04 | 0.04 | |
Debt to equity | 0.17 | 0.17 | 0.23 | 0.19 | 0.93 | |
Debt to assets | 0.11 | 0.11 | 0.16 | 0.14 | 0.39 | |
Net debt to EBITDA | 181.03 | -2.32 | -0.31 | -0.5 | 1.98 | |
Current ratio | 2.84 | 2.49 | 3.06 | 3.99 | 2.17 | |
Interest coverage | -0.33 | -38.04 | 48.74 | 42.66 | 6.85 | |
Income quality | 0.9 | 52.2 | 1.55 | 0.98 | 1.33 | |
Dividend Yield | 0 | 0.02 | 0.01 | 0.01 | 0.14 | |
Payout ratio | 0 | 21.12 | 0.26 | 0.17 | 3.3 | |
Sales general and administrative to revenue | 0.16 | 0.14 | 0.12 | 0.09 | 0.08 | |
Research and developement to revenue | 0.21 | 0.19 | 0.14 | 0.15 | 0.1 | |
Intangibles to total assets | 0.07 | 0.06 | 0.06 | 0.05 | 0.41 | |
Capex to operating cash flow | -1 | -0.59 | -0.28 | -0.27 | -0.21 | |
Capex to revenue | -0.13 | -0.1 | -0.06 | -0.05 | -0.06 | |
Capex to depreciation | -1.97 | -1.34 | -1.03 | -0.84 | -0.91 | |
Stock based compensation to revenue | 0.05 | 0.06 | 0.04 | 0.04 | 0.03 | |
Graham number | 12.98 | 2.12 | 16.52 | 19.89 | 26.54 | |
ROIC | 0 | -0.01 | 0.06 | 0.1 | 0.13 | |
Return on tangible assets | 0.09 | 0 | 0.1 | 0.13 | 0.15 | |
Graham Net | 0.31 | 0.45 | 0.34 | 1.54 | -8.96 | |
Working capital | 165.23M | 167.48M | 214.31M | 283.46M | 264.19M | |
Tangible asset value | 386.38M | 408.11M | 406.65M | 491.36M | 26.13M | |
Net current asset value | 95.8M | 97.17M | 92.11M | 164.99M | -383.89M | |
Invested capital | 0.17 | 0.17 | 0.23 | 0.19 | 0.93 | |
Average receivables | 48.95M | 56.04M | 72.66M | 83.95M | 101.96M | |
Average payables | 82.23M | 86.28M | 92.52M | 86.89M | 54.84M | |
Average inventory | 89.91M | 103.67M | 94.82M | 98.2M | 104.71M | |
Days sales outstanding | 51.73 | 69.27 | 65.81 | 65.08 | 65.11 | |
Days payables outstanding | 147.68 | 168.8 | 137.31 | 122.93 | 30.91 | |
Days of inventory on hand | 211.79 | 171.15 | 142.31 | 151.16 | 128.58 | |
Receivables turnover | 7.06 | 5.27 | 5.55 | 5.61 | 5.61 | |
Payables turnover | 2.47 | 2.16 | 2.66 | 2.97 | 11.81 | |
Inventory turnover | 1.72 | 2.13 | 2.56 | 2.41 | 2.84 | |
ROE | 0.13 | 0 | 0.14 | 0.17 | 0.22 | |
Capex per share | -0.83 | -0.72 | -0.57 | -0.46 | -0.72 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.61 | 2.69 | 2.74 | 3.35 | 3.36 | |
Net income per share | 0.66 | 0.5 | 0.49 | 0.91 | 0.68 | |
Operating cash flow per share | 0.29 | 0.78 | 1.03 | 1.19 | 0.45 | |
Free cash flow per share | 0.17 | 0.59 | 0.86 | 1 | 0.27 | |
Cash per share | 3.4 | 3.71 | 3.07 | 5.56 | 4.89 | |
Book value per share | 10.22 | 10.56 | 11.1 | 11.04 | 12.06 | |
Tangible book value per share | 9.5 | 9.84 | -0.68 | -0.45 | 0.49 | |
Share holders equity per share | 10.22 | 10.56 | 11.1 | 11.04 | 12.06 | |
Interest debt per share | 1.99 | 1.97 | 9.89 | 12.73 | 11.37 | |
Market cap | 1.45B | 1.95B | 3.05B | 2.48B | 3.28B | |
Enterprise value | 1.4B | 1.87B | 3.43B | 2.89B | 3.76B | |
P/E ratio | 10.68 | 18.72 | 29.2 | 12.6 | 22.67 | |
Price to sales ratio | 10.73 | 13.92 | 20.94 | 13.73 | 18.41 | |
POCF ratio | 95.17 | 48.26 | 55.56 | 38.55 | 137.4 | |
PFCF ratio | 162.53 | 63.06 | 66.53 | 45.8 | 227.36 | |
P/B Ratio | 2.74 | 3.55 | 5.18 | 4.17 | 5.13 | |
PTB ratio | 2.74 | 3.55 | 5.18 | 4.17 | 5.13 | |
EV to sales | 10.34 | 13.39 | 23.55 | 15.98 | 21.1 | |
Enterprise value over EBITDA | 36.89 | 56.06 | 93.02 | 39.7 | 55.45 | |
EV to operating cash flow | 91.66 | 46.41 | 62.49 | 44.85 | 157.48 | |
EV to free cash flow | 156.52 | 60.65 | 74.82 | 53.3 | 260.58 | |
Earnings yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
Free cash flow yield | 0.01 | 0.02 | 0.02 | 0.02 | 0 | |
Debt to equity | 0.19 | 0.19 | 0.9 | 1.13 | 0.93 | |
Debt to assets | 0.14 | 0.13 | 0.38 | 0.44 | 0.39 | |
Net debt to EBITDA | -1.41 | -2.23 | 10.3 | 5.58 | 7.07 | |
Current ratio | 3.99 | 3.86 | 1.53 | 2.1 | 2.17 | |
Interest coverage | 71.65 | 65.42 | -10.24 | 5.3 | 5.71 | |
Income quality | 0.45 | 1.55 | 2.1 | 1.31 | 0.66 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.06 | 0.18 | 0.38 | 0.04 | 0 | |
Sales general and administrative to revenue | 0.08 | 0.1 | 0.08 | 0.07 | 0.07 | |
Research and developement to revenue | 0.13 | 0.14 | 0.12 | 0.09 | 0.1 | |
Intangibles to total assets | 0.05 | 0.05 | 0.45 | 0.4 | 0.41 | |
Capex to operating cash flow | -0.41 | -0.23 | -0.16 | -0.16 | -0.4 | |
Capex to revenue | -0.05 | -0.07 | -0.06 | -0.06 | -0.05 | |
Capex to depreciation | -0.85 | -1.28 | -1.29 | -0.75 | -0.68 | |
Stock based compensation to revenue | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
Graham number | 12.28 | 10.91 | 11.08 | 15.06 | 13.61 | |
ROIC | 0.05 | 0.03 | 0.03 | 0.04 | 0.04 | |
Return on tangible assets | 0.05 | 0.04 | 0.03 | 0.05 | 0.04 | |
Graham Net | 1.57 | 1.84 | -9.3 | -9.35 | -8.96 | |
Working capital | 283.46M | 302.04M | 133.27M | 285.04M | 264.19M | |
Tangible asset value | 491.36M | 511.4M | -36.37M | -24.21M | 26.13M | |
Net current asset value | 164.99M | 182.59M | -404.48M | -406.49M | -383.89M | |
Invested capital | 0.19 | 0.19 | 0.9 | 1.13 | 0.93 | |
Average receivables | 88.72M | 95.17M | 103.71M | 113.27M | 117.72M | |
Average payables | 90.02M | 86.56M | 153.21M | 220.13M | 124.08M | |
Average inventory | 103.42M | 103.62M | 104.13M | 107.3M | 107.91M | |
Days sales outstanding | 59.31 | 65.16 | 65.5 | 60.06 | 58.08 | |
Days payables outstanding | 118.73 | 120.87 | 268.29 | 277.81 | 27.08 | |
Days of inventory on hand | 146 | 140.95 | 129.03 | 137.18 | 112.67 | |
Receivables turnover | 1.52 | 1.38 | 1.37 | 1.5 | 1.55 | |
Payables turnover | 0.76 | 0.74 | 0.34 | 0.32 | 3.32 | |
Inventory turnover | 0.62 | 0.64 | 0.7 | 0.66 | 0.8 | |
ROE | 0.06 | 0.05 | 0.04 | 0.08 | 0.06 | |
Capex per share | -0.12 | -0.18 | -0.17 | -0.19 | -0.18 |
AMPH Frequently Asked Questions
What is Amphastar Pharmaceuticals, Inc. stock symbol ?
Amphastar Pharmaceuticals, Inc. is a US stock , located in Rancho cucamonga of Ca and trading under the symbol AMPH
Is Amphastar Pharmaceuticals, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $35. The lowest prediction is $35 and the highest is $35
What is AMPH stock prediction ?
What is Amphastar Pharmaceuticals, Inc. stock quote today ?
Amphastar Pharmaceuticals, Inc. stock price is $43.91 today.
Is Amphastar Pharmaceuticals, Inc. stock public?
Yes, Amphastar Pharmaceuticals, Inc. is a publicly traded company.